32 results about "Tau protein" patented technology

This invention belongs to the field of biosensing and detection technology, specifically disclosing a Tau protein electrochemiluminescent aptamer sensor, its preparation method, and its application. The sensor uses a CsPbBr₃@PVP / Au composite material as the electrochemiluminescent substrate. A Tau protein-specific aptamer is immobilized on the substrate surface via Au-S bonds, and non-specific adsorption sites are blocked with 6-mercapto-1-hexanol. The CsPbBr₃@PVP / Au composite material is prepared by encapsulating CsPbBr₃ with PVP and then combining it with Au NPs. This invention utilizes the coordination passivation effect of PVP and CsPbBr₃ to significantly improve the aqueous stability and electrochemiluminescence efficiency of perovskite nanocrystals. Combined with the anchoring effect of AuNPs and the specific recognition effect of aptamers, it achieves ultrasensitive detection of Tau protein with a detection limit as low as 0.80 fg / mL. Furthermore, it exhibits excellent selectivity, stability, and detection accuracy in complex biological samples such as cerebrospinal fluid, providing a novel and efficient detection platform for the early diagnosis of Alzheimer's disease and showing promising clinical application prospects.

This invention discloses a polypeptide that inhibits the desimilarization activity of tau protein and its applications, belonging to the field of biomedical technology. The polypeptide of this invention is tau. 438 The peptide is obtained through endogenous tau protein synthesis. The peptide provided by this invention can inhibit tau protein desimulation and increase tau mimicry, exhibiting high specificity and safely and effectively improving cognitive and memory function in AD model mice.

The invention relates to methods and materials for use in treating neurodegenerative diseases associated with pathological protein aggregates and provides fusion proteins comprising: (i) a first portion comprising a sequence of a protein which aggregates pathologically in neurodegenerative disease, such as tau protein, and (ii) a second portion comprising a RING-type E3 ubiquitin ligase, a component of a RING-type E3 ubiquitin ligase complex, or a domain of either. These fusion proteins have utility in selectively or preferentially targeting pathogenic protein aggregates for degradation.

This invention belongs to the field of biochemistry technology, and relates to a near-infrared chemiluminescent probe responsive to tau protein, its preparation method, and its application. The preparation method of the near-infrared chemiluminescent probe includes the following steps: adding compound (I), compound (II), a catalyst, and an alkaline additive to a first solvent for reaction to obtain compound (III); adding compound (III), compound (IV), and piperidine to a second solvent for reaction to obtain compound (V); adding compound (V) and trifluoroacetic acid to a third solvent for reaction to obtain compound (VI); and adding compound (VI), compound (VII), and an acid compound to a fourth solvent for reaction to obtain the near-infrared chemiluminescent probe. The chemiluminescent probe of this invention exhibits high selectivity and efficient chemiluminescence capability, providing a promising tool for the diagnosis of Alzheimer's disease (AD). Its structural formula is: [Insert structural formula here].

The present application relates to the field of biological medical technology, in particular to a traditional Chinese medicine composition as GSK-3beta inhibitor and preparation and application thereof. The traditional Chinese medicine composition as GSK-3beta inhibitor comprises gastrodin and ganoderma triterpene, and the mass ratio of gastrodin and ganoderma triterpene is (1-4):1. The traditional Chinese medicine composition provided by the present application can inhibit the overexpression of GSK-3beta in AD model, thereby inhibiting the overphosphorylation of Tau protein and playing a protective role on Alzheimer's disease. In addition, the traditional Chinese medicine composition provided by the present application contains gastrodin and ganoderma triterpene, which are homoeopathic traditional Chinese medicine efficacy components, greatly improving the safety of the drug, and providing a train of thought for the application of the traditional Chinese medicine composition as a functional food.

An optical imaging system according to an embodiment disclosed in the present document may include: a laser module configured to radiate an ultrashort pulse laser beam; a microscope module configured to transmit the radiated ultrashort pulse laser beam to an eye of a subject and detect reflected light from the eye or (auto)fluorescence in the eye using an image sensor; a control module configured to generate a tau-related image in which a modification of tau proteins is detectable from the reflected light detected through the image sensor; and an output device configured to display the tau-related image.

The present invention relates to the biomedical and biopharmaceutical sectors. Specifically, it relates to a chimeric antigen comprising the combination of the amino- and carboxy-terminal regions of the amyloid-beta peptide (Aβ), the amino- and carboxy-terminal regions of the tau protein, and a T-cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's disease (AD). The chimeric antigen exerts its action by stimulating a multi-target humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This promotes the combined elimination of toxic Aβ and tau species from the brain, thereby preventing or significantly improving the clinical symptoms and neuropathology of AD.

The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of certain types of oligomers in a subject. More specifically, the drugs and compositions reduce or prevent the formation of oligomers formed from tau protein, TDP-43, Huntingtin's protein and / or alpha-synuclein. It further provides a method of reducing formation of or disrupting TDP-43, alpha-synuclein, Huntingtin's protein and / or tau protein oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.

This invention discloses the use of cyanidin anthocyanins or their pharmaceutically acceptable salts, esters, and solvates in the preparation of drugs for the prevention and / or treatment of neurodegenerative diseases. The cyanidin anthocyanins are selected from cyanidin-3-O-rutin glycoside, cyanidin-3-O-sophoroside, or cyanidin-3-O-xyloside. These compounds can inhibit acetylcholinesterase activity, upregulate α7 nicotinic acetylcholine receptor expression, and activate the PI3K / AKT / GSK3β signaling pathway, thereby inhibiting Tau protein hyperphosphorylation and reducing neuroinflammatory responses. Furthermore, it has been confirmed that cyanidin-3-O-rutin glycoside directly binds to acetylcholinesterase, verifying AChE as its key target, providing new natural active compounds and their mechanisms of action for the prevention and treatment of neurodegenerative diseases.

Phosphorylated human tau protein at amino acid serine 413 (pS413 tau) can serve as a biomarker for tauopathies such as Alzheimer's disease. Detecting and quantifying pS413 tau in biological samples such as cerebrospinal fluid can be used to develop therapies for certain tauopathies. However, pS413 tau is present at very low levels in biological samples. Accordingly, the present invention provides a highly sensitive assay method for detecting and quantifying pS413 tau in biological samples comprising a series of steps described herein.

The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.

The application provides a fluorescent probe for detecting Tau protein and a preparation method and application thereof, the fluorescent probe is a phenothiazine compound with a specific conjugated structure, has characteristic absorption in an ultraviolet-visible light region, produces stable fluorescent emission in a visible light to near infrared wave band, can be selectively combined with Tau protein aggregates and produce a significant fluorescent signal change, thereby realizing high-sensitivity detection and pathological evaluation of Tau protein abnormal deposition.

In one embodiment, a novel indanone derivative or a salt thereof and its uses are provided. According to one embodiment, the novel indanone derivative exhibits excellent efficacy in inhibiting and / or depolymerizing β-amyloid protein aggregates, inhibiting and / or depolymerizing Tau protein aggregates, and / or inhibiting Tau protein phosphorylation, and therefore can be effectively used for the prevention or treatment of degenerative brain diseases.

This invention discloses a wearable targeted static magnetic field device and its usage method for early intervention in Alzheimer's disease, belonging to the field of physical therapy equipment technology. The device consists of a permanent magnet array, a metal shield, a magnet support device, and a support shell suitable for wearing on the head. The device generates a constant static magnetic field spatial distribution with multiple focal points and a specific gradient within the wearer's skull through the arranged permanent magnet array. The characteristic parameters of this distribution include: multiple local intensity peaks of 10-50 mT and a spatial gradient of 0.5-5 T / m. As an intervention method, the static magnetic field can significantly inhibit Tau protein LLPS, reduce neuronal apoptosis, and improve the patient's cognitive function. This invention is a soft, elastic, wearable device that provides a novel, precisely targeted, and easy-to-use physical therapy solution for AD.

Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.

It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.

The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

This invention relates to the field of immunology, specifically disclosing an anti-Tau monoclonal antibody and its applications. The heavy chain has three CDR regions with amino acid sequences as shown in SEQ ID NO:1, 2, and 3, respectively; and the light chain has three CDR regions with amino acid sequences as shown in SEQ ID NO:4, 5, and 6, respectively. The anti-Tau monoclonal antibody provided by this invention can bind to the N-terminal projection region of Tau protein, specifically recognizing the N-terminal Thr95 / Thr101 phosphorylation modification site of Tau protein. It can be used for immunoblotting detection of Tau protein and its pathologically related components in human brain samples, for histological detection of Tau pathological structures in transgenic animal and human brain tissue samples, and for pathological staging studies of Tau protein-related diseases.

A method for inducing an immune response against tau protein in subjects with neurodegenerative diseases, disorders, or conditions (e.g., Alzheimer's disease) is described. The method comprises administering a liposome-initiating composition containing a tau peptide (preferably phosphorylated tau peptide) and a conjugate-enhancing composition containing a tau peptide (preferably phosphorylated tau peptide) conjugated to an immunogenic carrier.

This invention discloses a method for establishing Alzheimer's disease in tree shrews. The specific steps involve mixing an ethanol solution of 0.5 μg / μl Microcystin-LR with a muscarine solution, and then injecting 2 μl into each of the bilateral Meynert basal ganglia of the tree shrew. After administration, the tree shrew is fed normally for two weeks to complete the Alzheimer's disease model. The muscarine solution is prepared under sterile conditions by adding 200 μl of sterile saline to a vial containing 1 mg of muscarine, repeatedly pipetting to ensure complete dissolution, resulting in a concentration of 5 μg / μl. The Microcystin-LR solution is a commercially available product. This invention involves injecting a mixture of 0.1 μg MC-LR and 3 μg IBO solution into the bilateral Meynert basal ganglia of tree shrews, establishing a stable tree shrew AD model after two weeks. Three days after administration, tree shrews exhibited AD behavioral manifestations, such as lethargy and reduced activity. Two weeks later, the tree shrew brains showed typical AD pathological manifestations, including Aβ deposition and elevated expression levels at multiple phosphorylation sites of Tau protein.

The application belongs to the technical field of biological medicine, and relates to application of FcRn inhibitor efgartid in preparation of a medicine for treating Alzheimer's disease. In-vivo experiments prove that after abdominal cavity injection of APP / PS1 mice, the injection frequency is once a week, the injection lasts for four weeks, the injection dose is 10 mg / kg, and the efgartid can significantly reduce the serum IgG level of the APP / PS1 mice, relieve cerebral A beta pathological deposition, and reduce disease-related neuroinflammation and Tau protein phosphorylation. The application provides a new way for treating Alzheimer's disease.

Compounds comprising a triazole scaffold, compositions comprising same, and the use of such compounds and compositions to inhibit tubulin-associated unit (tau) protein and alpha-synuclein (α-syn) protein aggregation, including neurofibrillary tangles (NFTs) and Lewy bodies.

The present application relates to a tau protein detection kit of double antibody sandwich coupling DNAzyme and application thereof, relates to the technical field of biological detection, and comprises a first antibody coupling a first component of catalytically active DNAzyme, a second antibody coupling a second component of catalytically active DNAzyme, a fluorescent probe and a reaction buffer.The detection method of the present application can accurately capture the subtle signal of tau protein, and provides strong support for early diagnosis of neurodegenerative diseases such as Alzheimer's disease.